Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atorvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 10/20 | 0.97 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.97 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.97 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.97 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.97 |
| ▸ | RHOC | P08134 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.97 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.97 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.84 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.84 |
| ▸ | PDE6D | O43924 | 3/20 | 0.75 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atorvastatin SCHEMBL618614 | 1.00 | HMGCR (0.97) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL26978250 | 1.00 | HMGCR (0.97) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL14968747 | 1.00 | HMGCR (0.97) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL34266 | 1.00 | HMGCR (0.97) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL5451363 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL524785 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL28270206 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL7037657 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL1402150 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL28457 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299118-A1 | Coordinated Metabolic Reprogramming in Response to Productive Viral Infections | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2021-09-30 | — | — | US | disclosed |
| US-11083725-B2 | Coordinated metabolic reprogramming in response to productive viral infections | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2021-08-10 | — | — | US | disclosed |
| US-20170304293-A1 | COORDINATED METABOLIC REPROGRAMMING IN RESPONSE TO PRODUCTIVE VIRAL INFECTIONS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-10-26 | — | — | US | disclosed |
| CN-102702014-B | Method for preparing atorvastatin calcium intermediate | YANGZIJIANG PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOG PHARMACEUTICAL CO LTD | 2014-03-19 | — | — | CN | disclosed |
| CN-102702014-A | Method for preparing atorvastatin calcium intermediate | YANGZIJIANG PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOG PHARMACEUTICAL CO LTD | 2012-10-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299118-A1 | Coordinated Metabolic Reprogramming in Response to Productive Viral Infections | MAVS, ATF4, PC | HMGCR 1824/4885SLCO1B1 4164/4885ABCB11 3330/4885 |
| US-20170304293-A1 | COORDINATED METABOLIC REPROGRAMMING IN RESPONSE TO PRODUCTIVE VIRAL INFECTIONS | MAVS, ATF4, PC | HMGCR 1824/4885SLCO1B1 4164/4885ABCB11 3330/4885 |
| US-11083725-B2 | Coordinated metabolic reprogramming in response to productive viral infections | MAVS, ATF4, PC | HMGCR 1824/4885SLCO1B1 4164/4885ABCB11 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.